Gert Riethmüller

Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value.

G. Schlimok, G. Riethmüller, F. Wawroschek, 2001, The Journal of urology.

Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer.

J. Köllermann, K. Pantel, G. Riethmüller, 1995, European journal of cancer.

Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer

M. Mack, P. Kufer, G. Riethmüller, 1997, Cancer Immunology, Immunotherapy.

T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation.

U. Spengler, G. Riethmüller, A. Möller, 1992, Journal of hepatology.

p53 in non-small-cell lung cancer.

J. Izbicki, K. Pantel, B. Passlick, 1994, Journal of the National Cancer Institute.

Direct demonstration of an HLA-DR allotypic determinant on the low molecular weight (beta) subunit using a mouse monoclonal antibody specific for DR3

R. Wank, D. Schendel, T. Meo, 1982, The Journal of experimental medicine.

ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.

S. Braun, K. Pantel, L. Riethdorf, 2001, Cancer research.

Monoclonal antibodies in cancer therapy.

Judith P. Johnson, E. Schneider-Gädicke, Gert Riethmüller, 1993, Current opinion in immunology.

Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region.

K. Pantel, G. Riethmüller, B. Hell, 1995, International journal of oral and maxillofacial surgery.